{"nctId":"NCT00103740","briefTitle":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","startDateStruct":{"date":"2002-04"},"conditions":["Paget's Disease of Bone"],"count":185,"armGroups":[{"label":"Zoledronic acid and placebo to risedronate","type":"EXPERIMENTAL","interventionNames":["Drug: zoledronic acid","Drug: Placebo to risedronate","Drug: Calcium and vitamin D supplements"]},{"label":"Risedronate and placebo to zoledronic acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: placebo to zoledronic acid","Drug: Risedronate","Drug: Calcium and vitamin D supplements"]}],"interventions":[{"name":"zoledronic acid","otherNames":[]},{"name":"placebo to zoledronic acid","otherNames":[]},{"name":"Risedronate","otherNames":[]},{"name":"Placebo to risedronate","otherNames":[]},{"name":"Calcium and vitamin D supplements","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 30 years or older\n* SAP 2 times ULN\n* Confirmed diagnosis of Paget's disease of the bone (by x-ray, magnetic resonance imaging, computerized tomography, radioisotope imaging, etc.).\n* 90 days washout calcitonin\n* 180 day washout bisphosphonate\n\nExclusion Criteria:\n\n* Allergic reaction to bisphosphonates\n* History of upper GI disorders\n* History of iritis, uveitis\n* Calculated creatinine clearance \\< 30 ml/min at baseline\n* Evidence of vitamin D deficiency\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Who Had Therapeutic Response at 6 Months","description":"A therapeutic response was defined as a reduction of at least 75% from baseline (Visit 1) in serum alkaline phosphatase (SAP) excess (difference between measured level and midpoint to the normal range) or normalization of SAP at the end of six months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Change in Serum Alkaline Phosphatase in U/L at Day 28","description":"The percent change in serum alkaline phosphatase from baseline to Day 28 was measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.1","spread":"14.55"},{"groupId":"OG001","value":"-24.3","spread":"18.19"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10","description":"The percent change in serum C-telopeptide from baseline to Day 10 was measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.2","spread":"123.73"},{"groupId":"OG001","value":"-40.1","spread":"34.70"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Urine α-CTx in ug/mmol at Day 10","description":"The percent change in urine α-CTx from baseline to Day 10 was measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.5","spread":"39.33"},{"groupId":"OG001","value":"-28.7","spread":"68.22"}]}]}]},{"type":"SECONDARY","title":"Time to First Therapeutic Response","description":"Therapeutic response was defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess (difference between measured level and midpoint to the normal range) or normalization of serum alkaline phosphatase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28","description":"Normalization of serum alkaline phosphatase occurred if the serum alkaline phosphatase measurement fell within the normal range. Central laboratory reference ranges for serum alkaline phosphatase: 31-110 U/L (female \\& male 20-58 years) and 35-115 U/L (female \\& male \\>58 years).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pain Severity at Day 182","description":"Change in pain severity score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.74"},{"groupId":"OG001","value":"-0.1","spread":"2.02"}]}]}]},{"type":"SECONDARY","title":"Change in Pain Interference at Day 182","description":"Change in pain interference score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.97"},{"groupId":"OG001","value":"0.0","spread":"1.89"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period","description":"Extended observation period. A therapeutic response is defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess or normalization of serum alkaline phosphatase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Partial Disease Relapse During the Extended Observation Period","description":"Extended observation period. A partial disease relapse was defined as an increase in serum alkaline phosphatase \\>= 50% from the serum alkaline phosphatase measurement at Month 6 and at least 1.25 times the upper normal limit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Disease Relapse During the Extended Observation Period","description":"Extended observation period. A disease relapse was defined as the occurrence of a serum alkaline phosphatase level that was \\>= 80% of baseline serum alkaline phosphatase value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":88},"commonTop":["Influenza like illness","Headache","Diarrhoea","Nausea","Arthralgia"]}}}